TIMP3 and breast cancer: A total of 24 mammary tumour samples (divided into three groups, mentioned above) were initially included in the study to quantify the level of methylation status of three and six CpG sites in the RASSF1A (Fig. 5A) or TIMP3 (Fig. 5B) promoter, respectively.